Heron Therapeutics: Strong Q1 Performance and Product Portfolio Growth Reinforce Buy Rating

In a report released today, Serge Belanger from Needham maintained a Buy rating on Heron Therapeutics (HRTX – Research Report), with a price target of $4.00.

Serge Belanger has given his Buy rating due to a combination of factors including Heron Therapeutics’ strong financial performance in the first quarter of 2025. The company reported a revenue of $38.9 million, surpassing market expectations, largely driven by better-than-anticipated sales of Cinvanti and Aponvie. This positive performance led to an increase in the company’s adjusted EBITDA guidance for the year.
Belanger’s optimism is further supported by the anticipated growth of Heron Therapeutics’ product portfolio, particularly Zynrelef and Aponvie, which are expected to drive significant revenue growth. The focus on commercial execution and the potential resolution of financial concerns related to the 2026 convertible notes also contribute to the positive outlook, reinforcing the Buy rating and the price target of $4.

In another report released on April 25, Jefferies also maintained a Buy rating on the stock with a $6.00 price target.